Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F16%3AN0000020" target="_blank" >RIV/00209775:_____/16:N0000020 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/16:00093599
Result on the web
<a href="http://dx.doi.org/10.1016/S2213-8587(16)30041-9" target="_blank" >http://dx.doi.org/10.1016/S2213-8587(16)30041-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S2213-8587(16)30041-9" target="_blank" >10.1016/S2213-8587(16)30041-9</a>
Alternative languages
Result language
angličtina
Original language name
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Original language description
Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at a young age. As many as one in 200 people could have heterozygous familial hypercholesterolaemia, and up to one in 300 000 individuals could be homozygous. The phenotypes of heterozygous and homozygous familial hypercholesterolaemia overlap considerably; the response to treatment is also heterogeneous. In this Review, we aim to define a phenotype for severe familial hypercholesterolaemia and identify people at highest risk for cardiovascular disease, based on the concentration of LDL cholesterol in blood and individuals' responsiveness to conventional lipid-lowering treatment. We assess the importance of molecular characterisation and define the role of other cardiovascular risk factors and advanced subclinical coronary atherosclerosis in risk stratification. Individuals with severe familial hypercholesterolaemia might benefit in particular from early and more aggressive cholesterol-lowering treatment (eg, with PCSK9 inhibitors). In addition to better tailored therapy, more precise characterisation of individuals with severe familial hypercholesterolaemia could improve resource use.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
The Lancet. Diabetes and endocrinology
ISSN
2213-8587
e-ISSN
—
Volume of the periodical
4
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
850-861
UT code for WoS article
—
EID of the result in the Scopus database
—